SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ditchdigger who wrote (57229)5/2/2016 11:42:26 AM
From: Graham Osborn  Read Replies (2) of 78748
 
"While politicians scream the reality is treatment cost per patient hasn't really increased that much over the past decade. The ancillary cost savings as a result of treatment length being reduced from as much as a year down to 12 weeks add up in the over all cost of cure. Not to mention the increased % of successfully treated patients per treatment course."

While this might be true for Hep C, it isn't true for the wider space of chronic disease including Hep C and oncology. Price per treatment course is skyrocketing out of control. That's the problem for manufacturers claiming a lower total cost of care - their case is so unusual they are likely to get lumped into overall reimbursement or generic pathway reforms. GILD was on the recently published "hit list" of overpriced drugs along with CELG and some others I think.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News